Generation of EBV-specific T cells for adoptive immunotherapy: A novel protocol using formalin-fixed stimulator cells to increase biosafety

Journal of Immunotherapy

Volumn 30, Issue 8, 2007, Pages 817-824

  Hammer, Markus H ^a   Brestrich, Gordon ^a   Mittenzweig, Alexa ^a   Roemhild, Andy ^a   Zwinger, Sandra ^a   Subklewe, Marion ^a   Beier, Carola ^a   Kurtz, Andreas ^a   Babel, Nina ^a   Volk, Hans Dieter ^a   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adoptive immunotherapy; Antigen specific T cells; Cytokine secretion assay; Epstein Barr virus; Formalin fixation

Indexed keywords

FORMALDEHYDE;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BIOSAFETY; CELL COUNT; CELL EXPANSION; CELL LINE; CELL SELECTION; CELL STIMULATION; CYTOKINE RELEASE; EPSTEIN BARR VIRUS; GOOD MANUFACTURING PRACTICE; LYMPHOBLASTOID CELL LINE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FORMALDEHYDE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEOPLASMS; OLIGOPEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; TISSUE FIXATION; VIRAL MATRIX PROTEINS;

EID: 37349024300     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318155a11c     Document Type: Article

References (27)

1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208-2216.
2. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
3. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551-555.
4. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
5. Ho WY, Yee C, Greenberg PD. Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest. 2002;110:1415-1417.
6. Hammer MH, Meyer S, Brestrich G, et al. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol. 2005;35:2250-2258.
7. Ho WY, Blattman JN, Dossett ML, et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003;3:431-437.
8. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942-2949.
9. Leen AM, Sili U, Savoldo B, et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood. 2004;103:1011-1019. [Epub ahead of print October 2, 2003].
10. Moosmann A, Khan N, Cobbold M, et al. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood. 2002;100:1755-1764.
11. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-1166.
12. Amrolia PJ, Muccioli-Casadei G, Yvon E, et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003;102:2292-2299. [Epub ahead of print May 22, 2003].
13. Savoldo B, Huls MH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002;100:4059-4066. [Epub ahead of print August 1, 2002].
14. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
15. Locatelli F, Comoli P, Montagna D, et al. Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2004;17:479-492.
16. Bissinger AL, Rauser G, Hebart H, et al. Isolation and expansion of human cytomegalovirus-specific cytotoxic T lymphocytes using interferon-gamma secretion assay. Exp Hematol. 2002;30:1178-1184.
17. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med. 2001;7:1159-1162.
18. Savoldo B, Cubbage ML, Durett AG, et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002;168:909-918.
19. Wiesner M, Zentz C, Hammer MH, et al. Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines. Eur J Immunol. 2005;35:2110-2121.
20. Beck O, Topp MS, Koehl U, et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood. 2006;107:2562-2569. [Epub ahead of print December 1, 2005].
21. Lieberman J, Fabry JA, Shankar P, et al. Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res Hum Retroviruses. 1995;11:257-271.
22. Doubrovina ES, Doubrovin MM, Lee S, et al. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Clin Cancer Res. 2004;10:7207-7219.
23. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood. 2004;103:3565-3572. [Epub ahead of print December 11, 2003].
24. Sili U, Huls MH, Davis AR, et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003;26:241-256.
25. Aoi T, Nakano H, Tanaka Y, et al. Enhancement of antigen-presenting ability of B lymphoma cells by partial inhibition of protein synthesis through inducing B7-1 expression. Immunology. 1997;91:212-218.
26. Barisas BG, Wade WF, Jovin TM, et al. Dynamics of molecules involved in antigen presentation: effects of fixation. Mol Immunol. 1999;36:701-708.
27. Wilkie GM, Taylor C, Jones MM, et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother. 2004;27:309-316.